Evidence map›Paper›PMID 40469301›Full record

ArticleFrontiers in immunology2025

Case Report: Vanishing bile duct syndrome in Hodgkin's lymphoma: a case highlighting jaundice and lymphadenopathy as early clues.

Shiyu Ma, Dali Cai, Yuan Miao, Baocheng Deng, Xiaojing Yan, Ran Gao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shiyu MaDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Dali CaiDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yuan MiaoDepartment of Pathology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Baocheng DengThe Second Department of Infectious Diseases, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaojing YanDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ran GaoDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vanishing bile duct syndrome is a specific pathologic process characterized by ductopenia and intrahepatic cholestasis, which may be a unique paraneoplastic syndrome of Hodgkin's lymphoma with an unfavorable prognosis. We report a 34-year-old woman with acute jaundice and lymphadenopathy, which was subsequently confirmed to be Hodgkin's lymphoma with concurrent vanishing bile duct syndrome based on a liver biopsy. The patient agreed to combination chemotherapy with brentuximab vedotin and achieved a complete response. Liver function recovered within 4 months. This article reviews the literature and provides insight for addressing similar clinical challenges.

Indexed as

Hodgkin DiseaseJaundiceLymphadenopathyParaneoplastic SyndromesAdultAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinFemaleHumansBrentuximab Vedotinbrentuximab vedotin (BV)Hodgkin’s lymphomajaundiceliver biopsyvanishing bile duct syndrome

Identifiers

PMID40469301
PMCPMC12133851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.